Hany Elmariah, MD
Hematology · Stanford, CANPI 1427348044
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $3,850 of the $4,047 with a category attached, or 95.1%. Sobi, Inc accounts for 95.1% of it on its own, with 2 other manufacturers making up the rest. 2025 is the largest year on record at $3,957, more than ten times the $24 reported in 2019. That places this record below the midpoint for hematology clinicians in CA, where the typical reported total is $4,615.
Across 4 payments — averaging $1011.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sobi, Inc$4K
- Bristol Myers Squibb$131
- Medexus Pharma, Inc.$66
Across 4 payments — averaging $37,307 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Bristol Myers Squibb$139K
- National Marrow Donor Program$10K
What the payments were for
- Consulting fees$3,85095%
- Food & beverage$1975%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sobi, Inc | 1 | $3,850 |
| Bristol Myers Squibb | 2 | $131 |
| Medexus Pharma, Inc. | 1 | $66 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,047 in reported general payments places this provider in the 45th percentile of 178 hematology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JakafiRuxolitinib Phosphate | 20 | $343,402 |
| PrevymisLetermovir | 13 | $94,507 |
| Atovaquone | 32 | $12,111 |
| Acyclovir | 154 | $2,955 |
| Dexamethasone | 24 | $787 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 80 | $552 |
| Triamcinolone Acetonide | 15 | $221 |
| Ondansetron Hcl | 11 | $167 |
| Prednisone | 23 | $122 |
| Amlodipine Besylate | 26 | $100 |
| Tramadol Hcl | 11 | $55 |
Paid to pharmacies, not to this prescriber.
Other hematology in Stanford
- Everett MeyerStanford$2.1M
- Deepu MadduriStanford$348K
- Surbhi SidanaStanford$170K
- Michaela LiedtkeStanford$112K
- Sydney LuStanford$110K
- Saurabh DahiyaStanford$94K
- David MiklosStanford$90K
- Lori MufflyStanford$87K
- Ravindra MajetiStanford$58K
- Robert NegrinStanford$38K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.